Brightening the picture for Illumina Inc. were two pieces of news: the sale of its San Diego facilities for $42 million (with a 10-year lease-back agreement) and the settlement of a court battle with Applera Corp. (BioWorld Today)
Genentech Inc.'s stock was nicked more than 6 percent Friday by news of a "dear doctor" letter regarding the colorectal cancer drug Avastin, but on Monday showed signs of rebounding from concern that William Tanner, analyst with Leerink Swann & Co. in New York, called "overblown." (BioWorld Today)
The fates and fortunes of biotechnology firms can be as twisted as any crime novel's plot, but the treasure at the center of the action - some novel drug or set of patents - often remains preserved, like the jewel sought by desperate characters of fiction. (BioWorld Financial Watch)
